PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

GlobalData projects the global HIV marketplace — which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) — to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor (INI-) and protease inhibitor (PI-) based STRs, which include ViiV Healthcare’s dolutegravir/lamivudine, ViiV’s and Janssen’s dolutegravir/rilpivirine, Gilead’s bictegravir/emtricitabine/tenofovir alafenamide fumarate (TAF), Gilead’s and Janssen’s darunavir/cobicistat/emtricitabine/TAF, and ViiV’s long-acting injectable formulation composed of cabotegravir/rilpivirine. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Key Questions Answered

How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2015–2025?

What are the most promising late-stage pipeline drugs in HIV?

How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?

What are the remaining unmet needs in HIV treatment management?

What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Scope

Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline HIV market revenue from 2015–2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Gilead Sciences

ViiV Healthcare

Merck & Co.

Janssen (Johnson & Johnson)

Bristol-Myers Squibb

TaiMed Biologics*

Cytodyn*

  • Denotes a company without currently marketed HIV therapeutics

Gilead Sciences

ViiV Healthcare

Merck & Co.

Janssen (Johnson & Johnson)

Bristol-Myers Squibb

TaiMed Biologics*

Cytodyn*

  • Denotes a company without currently marketed HIV therapeutics

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Human Immunodeficiency Virus (HIV): Executive Summary

2.1 HIV Market ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Human Immunodeficiency Virus (HIV): Executive Summary

2.1 HIV Market Will Experience Modest Growth During the Forecast Period

2.2 Companies Leverage Partnerships to Develop New STRs and Fixed-Dose Combinations to Capture HIV Market Share

2.3 While HIV Therapies Continue to Raise the Bar on Efficacy, Safety, and Convenience, Unmet Needs Persist

2.4 Even in the Face of Strong Marketed and Pipeline Products, Opportunities Still Exist for Current and Future Players to Impact the HIV Marketplace

2.5 Novel STRs and FDCs With Improved Efficacy and Safety, and a Decreased Pill Burden, Are Expected to Dominate the Future HIV Treatment Landscape

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.1.1 The Viral Lifecycle

4.2 Pathophysiology

4.3 Staging and Symptoms

4.3.1 Acute Infection

4.3.2 Chronic Infection

4.3.3 Advanced Infection (AIDS)

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan, Brazil, and China

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.4.3 Sources Not Used

5.5 Epidemiological Forecast for HIV in the 8MM (2015–2025)

5.5.1 Total Prevalent Cases of HIV

5.5.2 Diagnosed Prevalent Cases of HIV

5.5.3 Age-Specific Diagnosed Prevalent Cases of HIV

5.5.4 Sex-Specific Diagnosed Prevalent Cases of HIV

5.5.5 Age-Standardized Diagnosed Prevalence of HIV

5.5.6 Diagnosed Prevalent Cases of HIV Treated with Antiretroviral Therapy

5.5.7 Diagnosed Prevalent Cases of HIV with Hepatitis B Virus Co-infection

5.5.8 Diagnosed Prevalent Cases of HIV with Hepatitis C Virus Co-infection

5.6 Epidemiological Forecast for HIV in Japan (2015–2025)

5.6.1 20-Year Diagnosed Prevalent Cases of HIV

5.6.2 Age-Specific 20-Year Diagnosed Prevalent Cases of HIV

5.6.3 Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV

5.6.4 Age-Standardized 20-Year Diagnosed Prevalence of HIV

5.6.5 20-Year Diagnosed Prevalent Cases of HIV Treated with Antiretroviral Therapy

5.6.6 20-Year Diagnosed Prevalent Cases of HIV with Hepatitis B Virus Co-infection

5.6.7 20-Year Diagnosed Prevalent Cases of HIV with Hepatitis C Virus Co-infection

5.7 Discussion

5.7.1 Epidemiological Forecast Insight

5.7.2 Limitations of Analysis

5.7.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Screening and Diagnosis

6.1.2 Treatment Guidelines and Leading Prescribed Drugs

6.1.3 Clinical Practice

6.2 US

6.2.1 Screening and Diagnosis

6.2.2 Clinical Practice

6.3 5EU

6.3.1 Screening and Diagnosis

6.3.2 Clinical Practice

6.4 Japan

6.4.1 Screening and Diagnosis

6.4.2 Clinical Practice

6.5 Brazil

6.5.1 Screening and Diagnosis

6.5.2 Clinical Practice

6.6 China

6.6.1 Screening and Diagnosis

6.6.2 Clinical Practice

7 Competitive Assessment

7.1 Overview

7.2 Product Profiles – Major Brands, Single-Tablet Regimens

7.2.1 Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)

7.2.2 Stribild (cobicistat/elvitegravir/emtricitabine/TDF)

7.2.3 Genvoya (cobicistat/elvitegravir/emtricitabine/TAF)

7.2.4 Triumeq (abacavir/dolutegravir/lamivudine)

7.2.5 Complera (emtricitabine/rilpivirine/TDF)

7.2.6 Odefsey (emtricitabine/rilpivirine/TAF)

7.3 Product Profiles – Major Brands, Fixed-Dose NRTI Backbones

7.3.1 Truvada (emtricitabine/TDF)

7.3.2 Descovy (emtricitabine/TAF)

7.4 Product Profiles – Major Brands, Integrase Inhibitors

7.4.1 Tivicay (dolutegravir)

7.4.2 Isentress (raltegravir)

7.5 Product Profiles – Major Brands, Protease Inhibitors

7.5.1 Prezcobix (darunavir/cobicistat)

7.5.2 Evotaz (atazanavir/cobicistat)

7.6 Other Approved Drugs

7.6.1 Overview

8 Unmet Needs Assessment and Opportunity Analysis

8.1 Overview

8.2 Long-Acting Regimens that Require Less-Frequent Administration

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Enhanced Public Awareness Initiatives Focused on Minimizing the Stigma Associated with HIV Infection

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Improved Physician Education Tools That Emphasize the Importance of Early Testing and Diagnosis

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Safe and Efficacious Therapies for Patients with Drug-Resistant HIV Strains

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

8.6 Therapies with Improved Safety and Tolerability Profiles

8.6.1 Unmet Need

8.6.2 Gap Analysis

8.6.3 Opportunity

8.7 Progress Towards a Functional Cure

8.7.1 Unmet Need

8.7.2 Gap Analysis

8.7.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Bictegravir/Emtricitabine/TAF

9.2.2 Dolutegravir/Lamivudine

9.2.3 Cobicistat/Darunavir/Emtricitabine/TAF

9.2.4 Doravirine/Lamivudine/TDF

9.2.5 Dolutegravir/Rilpivirine

9.2.6 Cabotegravir/Rilpivirine

9.2.7 Fostemsavir

9.2.8 Ibalizumab

9.2.9 PRO-140

9.3 Other Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Gilead Sciences

10.3.2 ViiV Healthcare

10.3.3 Janssen

10.3.4 Merck & Co.

10.3.5 Bristol-Myers Squibb

10.3.6 Minor and Emerging Players

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 Brazil

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

11.6 China

11.6.1 Forecast

11.6.2 Key Events

11.6.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.4 Forecasting Methodology

12.4.1 Total and Diagnosed Prevalent Cases of HIV (8MM)

12.4.2 20-Year Diagnosed Prevalent Cases of HIV (Japan)

12.4.3 Diagnosed Prevalent Cases of HIV Treated with ART

12.4.4 Drugs Included in Each Therapeutic Class

12.4.5 Launch and Patent Expiry Dates

12.4.6 General Pricing Assumptions

12.4.7 Individual Drug Assumptions

12.4.8 Generic Erosion

12.4.9 Pricing of Pipeline Agents

12.5 Primary Research – KOLs and Payers Interviewed for this Report

12.5.1 KOLs

12.5.2 Payers

12.6 Primary Research – Prescriber Survey

12.7 About the Authors

12.7.1 Analyst

12.7.2 Therapy Area Director

12.7.3 Epidemiologists

12.7.4 Global Director of Therapy Analysis and Epidemiology

12.7.5 Global Head and EVP of Healthcare Operations and Strategy

12.8 About GlobalData

12.9 Contact Us

12.10 Disclaimer

List of tables

Table 1: HIV: Key Metrics in the Nine Major Pharmaceutical Markets

Table 2: CDC and WHO Staging Classification of HIV-1 Infection in Patients ≥6 Years ...

Table 1: HIV: Key Metrics in the Nine Major Pharmaceutical Markets

Table 2: CDC and WHO Staging Classification of HIV-1 Infection in Patients ≥6 Years

Table 3: Symptoms of Acute, Chronic, and Advanced Stages of HIV Infection

Table 4: Risk Factors and Comorbidities for HIV

Table 5: 5EU, Total Prevalence of HIV in Men and Women (%), All Ages, Selected Years, 2001–2015

Table 6: 8MM, Sources of HIV Total Prevalence Data

Table 7: 8MM, Sources of HIV Diagnosed Prevalence Data

Table 8: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan

Table 9: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV on ART

Table 10: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV with HBV Co-infection

Table 11: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV with HCV Co-infection

Table 12: 8MM, Total Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 13: 8MM, Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 14: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, 2015, Cases (N) and Proportions (Row %)

Table 15: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, 2015 (Row %)

Table 16: 8MM, Diagnosed Prevalent HIV Cases Treated with ART, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 17: 8MM, Diagnosed Prevalent HIV Cases with HBV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 18: 8MM, Diagnosed Prevalent HIV Cases with HCV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 19: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 20: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Both Sexes, N, 2015 (Row %)

Table 21: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N, 2015 (Row %)

Table 22: Japan, 20-Year Diagnosed Prevalent HIV Cases Treated with ART, All Ages, Both Sexes 2015–2025, Cases (N) and Proportions (%)

Table 23: Japan, 20-Year Diagnosed Prevalent HIV Cases with HBV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 24: Japan, 20-Year Diagnosed Prevalent HIV Cases with HCV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 25: Treatment Guidelines for HIV-1 Used in the 9MM

Table 26: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2015

Table 27: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2016

Table 28: Diagnosis and Treatment of HIV Infection, Country Profile – US

Table 29: Switching of ART Regimens in the US, 2015

Table 30: Diagnosis and Treatment of HIV Infection, Country Profile – 5EU

Table 31: CD4+ Thresholds and Corresponding Recommendations for the Initiation of ART in Asymptomatic Patients in the 5EU

Table 32: Switching of ART Regimens in the 5EU, 2015

Table 33: Diagnosis and Treatment of HIV Infection, Country Profile – Japan

Table 34: Switching of ART Regimens in Japan, 2015

Table 35: Diagnosis and Treatment of HIV Infection, Country Profile – Brazil

Table 36: Switching of ART Regimens in Brazil, 2015

Table 37: Diagnosis and Treatment of HIV Infection, Country Profile – China

Table 38: Switching of ART Regimens in China, 2015

Table 39: Leading Branded Treatments for HIV, 2016

Table 40: Product Profile – Atripla

Table 41: Efficacy of Atripla Compared with Combivir + Sustiva

Table 42: Safety of Atripla – Frequency of AEs Compared with Combivir + Sustiva

Table 43: Atripla SWOT Analysis, 2016

Table 44: Product Profile – Stribild

Table 45: Pivotal Phase III Trials of Stribild in Treatment-Naïve Patients

Table 46: Stribild’s Adverse Reactions – Pooled Results From Two Phase III Clinical Trials

Table 47: Stribild SWOT Analysis, 2016

Table 48: Product Profile – Genvoya

Table 49: Efficacy of Genvoya and Stribild in Studies 104 and 111

Table 50: Adverse Events Associated with Genvoya vs. Stribild Therapy in Two Phase III Clinical Studies

Table 51: Genvoya SWOT Analysis, 2016

Table 52: Product Profile – Triumeq

Table 53: Virologic Efficacy of Triumeq in the Phase III SINGLE Study

Table 54: Triumeq’s Safety – Adverse Reactions Reported at 96 Weeks in the SINGLE Study

Table 55: Triumeq SWOT Analysis, 2016

Table 56: Product Profile – Complera

Table 57: ECHO and THRIVE Studies of the Complera and Atripla Multi-tablet Regimens

Table 58: Complera SWOT Analysis, 2016

Table 59: Product Profile – Odefsey

Table 60: Safety of Odefsey – Frequency of AEs

Table 61: Odefsey SWOT Analysis, 2016

Table 62: Product Profile – Truvada

Table 63: Truvada’s Efficacy – Results of the SWIFT Trial at 48 Weeks

Table 64: Truvada SWOT Analysis, 2016

Table 65: Product Profile – Descovy

Table 66: Safety of Descovy – Frequency of AEs

Table 67: Descovy SWOT Analysis, 2016

Table 68: Product Profile – Tivicay

Table 69: Pivotal Phase III Trials of Tivicay

Table 70: Tivicay’s Safety – Adverse Reactions Reported in the 48-Week SINGLE Study

Table 71: Tivicay SWOT Analysis, 2016

Table 72: Product Profile – Isentress

Table 73: Percentage of Patients with HIV-1 RNA Levels <50 Copies/mL from the SMARTMRK Study

Table 74: Isentress’ Safety – Adverse Reactions Reported in the SMARTMRK Study

Table 75: Isentress SWOT Analysis, 2016

Table 76: Product Profile – Prezcobix

Table 77: Efficacy of Prezcobix in the Phase III Trial

Table 78: Prezcobix SWOT Analysis, 2016

Table 79: Product Profile – Evotaz

Table 80: Efficacy of BMS’ Evotaz in the Phase III Study

Table 81: Evotaz SWOT Analysis, 2016

Table 82: Other Approved HIV Drugs

Table 83: Unmet Need and Opportunity in HIV

Table 84: Key Late-Stage Pipeline Agents for HIV Therapeutics, 2016

Table 85: Comparison of Therapeutic Classes in Late-Stage Development for HIV, 2015–2025

Table 86: Product Profile – Bictegravir/Emtricitabine/TAF

Table 87: Gilead’s Bictegravir/Emtricitabine/TAF – Phase III Clinical Trials

Table 88: Bictegravir/Emtricitabine/TAF SWOT Analysis, 2016

Table 89: Product Profile – Dolutegravir/Lamivudine

Table 90: ViiV’s Dolutegravir/Lamivudine – Phase III Clinical Trials

Table 91: Dolutegravir/Lamivudine Safety – Adverse Reactions Reported at 24 Weeks – PADDLE Study

Table 92: Dolutegravir/Lamivudine SWOT Analysis, 2016

Table 93: Product Profile – Cobicistat/Darunavir/Emtricitabine/TAF

Table 94: Janssen’s Cobicistat/Darunavir/Emtricitabine/TAF – Phase III Clinical Trials

Table 95: Cobicistat/Darunavir/Emtricitabine/TAF SWOT Analysis, 2016

Table 96: Product Profile – Doravirine/Lamivudine/TDF

Table 97: Efficacy Results of a Phase II Dose-Ranging Study of Doravirine Compared with a Standard Dose of Efavirenz

Table 98: Doravirine/Lamivudine/TDF SWOT Analysis, 2016

Table 99: Product Profile – Dolutegravir/Rilpivirine

Table 100: Tivicay’s Safety – Adverse Reactions Reported in the 48-Week SINGLE Study

Table 101: Dolutegravir/Rilpivirine SWOT Analysis, 2016

Table 102: Product Profile – Cabotegravir/Rilpivirine

Table 103: Cabotegravir/Rilpivirine SWOT Analysis, 2016

Table 104: Product Profile – Fostemsavir

Table 105: Fostemsavir SWOT Analysis, 2016

Table 106: Product Profile – Ibalizumab

Table 107: TaiMed’s and Theratechnologies’ Ibalizumab – Phase IIb Clinical Trial Outcomes

Table 108: Ibalizumab SWOT Analysis, 2016

Table 109: Product Profile – PRO-140

Table 110: PRO-140 SWOT Analysis, 2016

Table 111: Other Drugs in Phase II of Clinical Development for HIV, 2016

Table 112: Key Companies in the HIV Market in the 9MM, 2016

Table 113: Gilead Sciences’ HIV Portfolio Assessment, 2016

Table 114: ViiV Healthcare’s HIV Portfolio Assessment, 2016

Table 115: Janssen’s HIV Portfolio Assessment, 2016

Table 116: Merck & Co.’s HIV Portfolio Assessment, 2016

Table 117: BMS’ HIV Portfolio Assessment, 2016

Table 118: Global (9MM) Sales Forecasts ($m) for HIV, 2015–2025

Table 119: HIV Therapeutics Market – Global Drivers and Barriers, 2015–2025

Table 120: Sales Forecasts ($m) for HIV in the US, 2015–2025

Table 121: Key Events Impacting Sales for HIV Therapeutics in the US, 2015–2025

Table 122: HIV Therapeutics Market – Drivers and Barriers in the US, 2015‒2025

Table 123: Number of People Living with HIV Who Received ART in the 5EU, and Sales of HIV Therapeutics ($m), 2015

Table 124: Sales Forecasts ($m) for HIV in the 5EU, 2015–2025

Table 125: Key Events Impacting Sales for HIV in the 5EU, 2015–2025

Table 126: HIV Therapeutics Market – Drivers and Barriers in the 5EU, 2015‒2025

Table 127: Sales Forecasts ($m) for HIV in Japan, 2015–2025

Table 128: Key Events Impacting Sales for HIV Therapeutics in Japan, 2015–2025

Table 129: Sales Forecasts ($m) for HIV in Brazil, 2015–2025

Table 130: Key Events Impacting Sales for HIV Therapeutics in Brazil, 2015–2025

Table 131: HIV Therapeutics Market – Drivers and Barriers in Brazil, 2015‒2025

Table 132: Sales Forecasts ($m) for HIV in China, 2015–2025

Table 133: Key Events Impacting Sales of HIV Therapeutics in China, 2015–2025

Table 134: HIV Therapeutics Market – Drivers and Barriers in China, 2015‒2025

Table 135: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM

Table 136: Patent Expiry Dates for HIV Therapeutics Across the 9MM

Table 137: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of figures

Figure 1: Global (9MM) Sales for HIV by Country/Region, 2015 and 2025

Figure 2: Company Portfolio Gap Analysis in HIV, 2015–2025

Figure 3 ...

Figure 1: Global (9MM) Sales for HIV by Country/Region, 2015 and 2025

Figure 2: Company Portfolio Gap Analysis in HIV, 2015–2025

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2015–2025

Figure 4: Cartoon Depicting the HIV Lifecycle

Figure 5: Global Overview of HIV, Men and Women, All Ages, 1990–2015

Figure 6: 8MM, Total Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Figure 7: 8MM, Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Figure 8: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, N, Select Years, 2015–2025

Figure 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, All Ages, N, Select Years, 2015–2025

Figure 10: 8MM, Age-Standardized Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015

Figure 11: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Figure 12: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015

Figure 13: HIV Disease Management Flowchart

Figure 14: HIV – Phase III Pipeline, 2016

Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2015–2025

Figure 16: Company Portfolio Gap Analysis in HIV, 2015–2025

Figure 17: Global (9MM) Sales for HIV by Country/Region, 2015 and 2025

Figure 18: Global (9MM) Sales for HIV by Drug Class, 2015 and 2025

Figure 19: Sales for HIV by Drug Class in the US, 2015 and 2025

Figure 20: Sales for HIV by Drug Class in the 5EU, 2015 and 2025

Figure 21: Sales for HIV by Drug Class in Japan, 2015 and 2025

Figure 22: Sales for HIV by Drug Class in Brazil, 2015 and 2025

Figure 23: Sales for HIV by Drug Class in China, 2015 and 2025

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports